Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

For Biogen, dapirolizumab pegol is part of a push ... also partnered with UCB – and felzartamab, an anti-CD38 antibody for IgA nephropathy (IgAN) and other diseases, licensed from Human ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots in Cambridge. That said, the company won’t be moving far from its ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

Biogen signed a 585K SF lease at the 75 Broadway St. development in Cambridge, the company announced Monday morning. It plans to move to the building in 2028 as its global headquarters.

That study used our assay to monitor response to felzartamab for patients at risk for kidney transplant rejection. This study led to breakthrough designation for the drug from the FDA. Importantly ...